AG
TBPH icon

Algert Global’s Theravance Biopharma TBPH Stock Holding History

Algert Global’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-199,705
Closed -$2.92M – 1316
2025
Q3 		$2.92M Buy
+199,705
New +$2.52M 0.05% 570
2024
Q4 		– Sell
-105,609
Closed -$851K – 1326
2024
Q3 		$851K Buy
+105,609
New +$915K 0.02% 785
2022
Q4 		– Sell
-30,700
Closed -$311K – 1286
2022
Q3 		$311K Sell
30,700
-39,190
-56% -$367K 0.02% 943
2022
Q2 		$633K Buy
69,890
+49,160
+237% +$453K 0.05% 678
2022
Q1 		$198K Sell
20,730
-11,000
-35% -$108K 0.01% 1054
2021
Q4 		$351K Buy
31,730
+13,350
+73% +$116K 0.04% 673
2021
Q3 		$136K Buy
+18,380
New +$206K 0.02% 951

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Algert Global's TBPH Position: Q4 2025 in Review

Algert Global sold out of Theravance Biopharma (TBPH) in Q4 2025, closing a stake of 199,705 shares — an estimated $2.92M sold.

Algert Global first reported a position in TBPH in Q3 2021 and held it in 7 quarters. The position peaked at $2.92M in Q3 2025. 169 funds tracked by Wall St. Rank hold TBPH as of Q4 2025.

  • Algert Global reported no remaining Theravance Biopharma position as of Q4 2025 after selling out during the quarter.
  • Algert Global sold 199,705 Theravance Biopharma shares in Q4 2025, an estimated $2.92M.
  • Algert Global first reported a position in Theravance Biopharma in Q3 2021 and held it in 7 quarters.
  • Algert Global's Theravance Biopharma position peaked at $2.92M in Q3 2025.
  • 169 funds tracked by Wall St. Rank held Theravance Biopharma as of Q4 2025.

Based on Algert Global's 13F filing for Q4 2025, filed 17 Feb 2026.